William C. Cromwell
About
William C. Cromwell is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Cancer Research.
According to data from OpenAlex, William C. Cromwell has authored 33 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Surgery, 19 papers in Endocrinology, Diabetes and Metabolism and 8 papers in Cancer Research. Recurrent topics in William C. Cromwell's work include Lipoproteins and Cardiovascular Health (25 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (18 papers) and Cancer, Lipids, and Metabolism (8 papers). William C. Cromwell is often cited by papers focused on Lipoproteins and Cardiovascular Health (25 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (18 papers) and Cancer, Lipids, and Metabolism (8 papers). William C. Cromwell collaborates with scholars based in United States, Canada and Brazil. William C. Cromwell's co-authors include James D. Otvos, Elias J. Jeyarajah, JoAnn Flaim, Katarina Byström, Maurice R. Eftink, Paul Ziajka, Christie M. Ballantyne, Peter P. Tóth, Anne C. Goldberg and Jennifer G. Robinson and has published in prestigious journals such as The Lancet, Circulation and Journal of the American College of Cardiology.
In The Last Decade
William C. Cromwell
33 papers receiving 3.7k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| William C. Cromwell United States | 18 | 2.3k | 1.6k | 891 | 795 | 698 | 33 | 3.9k | ||
| Hanna Mäenpää Finland | 22 | 2.0k 0.9× | 1.7k 1.1× | 746 0.8× | 825 1.0× | 945 1.4× | 54 | 4.8k | ||
| Marina Cuchel United States | 26 | 3.3k 1.4× | 2.3k 1.4× | 1.2k 1.4× | 1.2k 1.5× | 969 1.4× | 81 | 5.0k | ||
| Liam R. Brunham Canada | 41 | 3.5k 1.5× | 1.4k 0.9× | 1.1k 1.2× | 945 1.2× | 2.0k 2.9× | 133 | 6.0k | ||
| Eleni Bairaktari Greece | 36 | 1.4k 0.6× | 1.1k 0.7× | 517 0.6× | 501 0.6× | 946 1.4× | 146 | 3.9k | ||
| Donald M. Black United States | 33 | 1.8k 0.8× | 787 0.5× | 414 0.5× | 570 0.7× | 1.1k 1.6× | 104 | 3.8k | ||
| M.J. Whiting Australia | 20 | 1.6k 0.7× | 1.7k 1.1× | 733 0.8× | 329 0.4× | 948 1.4× | 39 | 3.7k | ||
| Michel Farnier France | 37 | 4.9k 2.2× | 1.7k 1.1× | 1.1k 1.2× | 1.0k 1.3× | 627 0.9× | 196 | 6.3k | ||
| Tim Crowe United States | 20 | 5.6k 2.4× | 1.9k 1.2× | 2.1k 2.4× | 994 1.3× | 669 1.0× | 38 | 7.3k | ||
| Martin Craig United Kingdom | 15 | 3.0k 1.3× | 1.1k 0.7× | 1.4k 1.5× | 461 0.6× | 193 0.3× | 33 | 4.0k | ||
| R.M. Krauss United States | 10 | 1.7k 0.7× | 2.0k 1.2× | 667 0.7× | 581 0.7× | 376 0.5× | 14 | 2.9k |
Countries citing papers authored by William C. Cromwell
Since
Specialization
Citations
This map shows the geographic impact of William C. Cromwell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William C. Cromwell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William C. Cromwell more than expected).
Fields of papers citing papers by William C. Cromwell
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by William C. Cromwell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William C. Cromwell. The network helps show where William C. Cromwell may publish in the future.
Co-authorship network of co-authors of William C. Cromwell
This figure shows the co-authorship network connecting the top 25 collaborators of William C. Cromwell. A scholar is included among the top collaborators of William C. Cromwell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William C. Cromwell. William C. Cromwell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Norwitz, Nicholas G. & William C. Cromwell. (2024). Oreo Cookie Treatment Lowers LDL Cholesterol More Than High-Intensity Statin therapy in a Lean Mass Hyper-Responder on a Ketogenic Diet: A Curious Crossover Experiment. Metabolites. 14(1). 73–73.
2.
Myers, Kelly D., Joshua W. Knowles, Michael D. Shapiro, et al.. (2019). Precision screening for familial hypercholesterolaemia: a machine learning study applied to electronic health encounter data. The Lancet Digital Health. 1(8). e393–e402.
3.
Sniderman, Allan D., Patrick Couture, Seth S. Martin, et al.. (2018). Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding. Journal of Lipid Research. 59(7). 1266–1275.
4.
Grabner, Michael, Deborah A. Winegar, Rajeshwari Punekar, et al.. (2016). Cost Effectiveness of Achieving Targets of Low-Density Lipoprotein Particle Number Versus Low-Density Lipoprotein Cholesterol Level. The American Journal of Cardiology. 119(3). 404–409.
5.
Tehrani, David M., Yanglu Zhao, Michael J. Blaha, et al.. (2016). Discordance of Low-Density Lipoprotein and High-Density Lipoprotein Cholesterol Particle Versus Cholesterol Concentration for the Prediction of Cardiovascular Disease in Patients With Metabolic Syndrome and Diabetes Mellitus (from the Multi-Ethnic Study of Atherosclerosis [MESA]). The American Journal of Cardiology. 117(12). 1921–1927.
6.
Santos, Raúl D., Frederick J. Raal, Joanne M. Donovan, & William C. Cromwell. (2014). Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia. Journal of clinical lipidology. 9(2). 201–209.
7.
Thomas, Gregory S., William C. Cromwell, Shariq Ali, et al.. (2013). Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces Atherogenic Lipoproteins in Patients With Severe Hypercholesterolemia at High Cardiovascular Risk. Journal of the American College of Cardiology. 62(23). 2178–2184.
8.
Davidson, Michael H., Christie M. Ballantyne, Terry A. Jacobson, et al.. (2011). Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. Journal of clinical lipidology. 5(5). 338–367.
9.
Goldberg, Anne C., Paul N. Hopkins, Peter P. Tóth, et al.. (2011). Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients. Journal of clinical lipidology. 5(3). 133–140.
10.
Goldberg, Anne C., Jennifer G. Robinson, William C. Cromwell, Joyce L. Ross, & Paul Ziajka. (2011). Future issues, public policy, and public awareness of Familial Hypercholesterolemias: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. Journal of clinical lipidology. 5(3). S46–S51.
11.
Goldberg, Anne C., Paul N. Hopkins, Peter P. Tóth, et al.. (2011). Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients. Journal of clinical lipidology. 5(3). S1–S8.
12.
Cromwell, William C., Robert Dufour, Claude Gagné, et al.. (2010). Abstract 19931: Mipomersen, An Apolipoprotein B Synthesis Inhibitor, Reduces Small LDL Particle Number and Increases LDL Particle Size in Patients with Heterozygous Familial Hypercholestrolemia and Coronary Artery Disease. Circulation. 122(21). c4305–c4305.
13.
Raal, Frederick J., Raúl D. Santos, Dirk Blom, et al.. (2010). Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. The Lancet. 375(9719). 998–1006.
14.
Cromwell, William C., Dirk Blom, A. David Marais, et al.. (2010). P431 MIPOMERSEN, AN apo B SYNTHESIS INHIBITOR, PREFERENTIALLY REDUCES SMALL LDL PARTICLE NUMBER AND INCREASES LDL PARTICLE SIZE IN HoFH PATIENTS. Atherosclerosis Supplements. 11(2). 107–108.
15.
Cromwell, William C. & T. A. Barringer. (2009). Low-density lipoprotein and apolipoprotein B: Clinical use in patients with coronary heart disease. Current Cardiology Reports. 11(6). 468–475.
16.
Cromwell, William C.. (2007). High-density lipoprotein associations with coronary heart disease: Does measurement of cholesterol content give the best result?. Journal of clinical lipidology. 1(1). 57–64.
17.
Cromwell, William C., James D. Otvos, Michelle J. Keyes, et al.. (2007). LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study—Implications for LDL management. Journal of clinical lipidology. 1(6). 583–592.
18.
Cromwell, William C. & James D. Otvos. (2006). Heterogeneity of Low-Density Lipoprotein Particle Number in Patients With Type 2 Diabetes Mellitus and Low-Density Lipoprotein Cholesterol <100 mg/dl. The American Journal of Cardiology. 98(12). 1599–1602.
19.
Cromwell, William C. & James D. Otvos. (2004). Low-density lipoprotein particle number and risk for cardiovascular disease. Current Atherosclerosis Reports. 6(5). 381–387.
20.
Otvos, James D., Elias J. Jeyarajah, & William C. Cromwell. (2002). Measurement issues related to lipoprotein heterogeneity. The American Journal of Cardiology. 90(8). 22–29.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Hanna Mäenpää Breakdown of academic impact, for papers by Marina Cuchel Breakdown of academic impact, for papers by Liam R. Brunham Breakdown of academic impact, for papers by Eleni Bairaktari Breakdown of academic impact, for papers by Donald M. Black Breakdown of academic impact, for papers by M.J. Whiting Breakdown of academic impact, for papers by Michel Farnier Breakdown of academic impact, for papers by Tim Crowe Breakdown of academic impact, for papers by Martin Craig Breakdown of academic impact, for papers by R.M. Krauss